Hitiq Limited · ASX:HIQ
Hitiq — Investor Presentation (November 2022)
39 slides from Hitiq's investor presentation, Nov 1, 2022
Slide 1: Capital Raising & Corporate Presentation
Capital Raising & Corporate Presentation November 2022 empowering advanced concussion management
Slide 2: Important Notice and Disclaimer
Disclaimer 2 IMPORTANT NOTICE AND DISCLAIMER This presentation has been prepared by HITIQ Limited (HIQ) and is provided for general information purposes only. No party other than HITIQ has authorised or caused the issue of this document, or takes responsibility for, or makes any statements, represen
Slide 3: Capital Raising Overview
Capital Raising Overview Renounceable Rights Issue Offer
Slide 4: Corporate Summary. Capital Structure
Capital Structure 4 Corporate Summary. Capital Structure (27 October 2022) Shareholders ASX Code HIQ Top 20 Shareholders 36% Share Price $0.041 15% Shares on Issue 132.4 M Directors and Management Top 20 Unlisted Options 28.2 M 64% 36% Others Market Capitalisation $5.4M Cash in bank (30 Sep 2022) $1
Slide 5: Renounceable Rights Issue Offer
Capital Raising 5 Renounceable Rights Issue Offer. KEY DETAILS OF THE OFFER > 8 New Shares for every 5 Shares held at the Record Date at the Issue Price plus; > 1 Option for every 1 New Share subscribed under the Offer. Offer to Eligible Shareholders > Option means a New Option to purchase a Share w
Slide 6: Use of Funds
Capital Raising 6 Use of Funds. The proposed capital raise will: Sales & marketing of consumer facing product suite $0.70m ► Progress commercialisation activities Further development technology platform including within the consumer market. $1.9m virtual reality pre-clinical activities ► Assist in l
Slide 7: Timetable
Capital Raising 7 Timetable. Indicative Rights Issue Timetable1 Event Date Rights Issue announcement and company resumes trading Tuesday, 1 November 2022 Record Date Thursday, 10 November 2022 Dispatch of Prospectus and Rights Issue Offer opens Monday, 14 November 2022 Rights trading ends at close o
Slide 8: Compelling opportunity with large potential upside
Highlights 8 Compelling opportunity with large potential upside. ► Global technology -led concussion management opportunity ► Disruptive technology with multi billion -dollar addressable markets (+$8b) ► Significant brain impact databank asset across major sporting codes ► Targeting growth in existi
Slide 9: Large unmet market need
Problem 9 Large unmet market need; There is no widely implemented solution to solve for better managing concussion-brain injury in sports. ► An athlete who sustains a concussion is 4-6 times more likely to sustain a Concussion lawsuits 10-20% of all contact challenging duty of care sport athletes su
Slide 10: Fundamental failure points across current protocols
Current Standard of Care 10 Fundamental failure points across current protocols lead to poor health outcomes & governance risk exposure. Athlete Journey BASELINE CONCUSSION 0-15 24-72 7-14 POST TESTING EVENT MINUTES HRS DAYS RETURN Point of care Follow Up Symptom Based No Longitudinal Elite athletes
Slide 11: What We Aim To Achieve
VISION What We Aim To Achieve EMPOWER CLINICIANS, PROTECT ATHLETES & SERVE LEAGUES AROUND THE GLOBE WITH QUALITY DATA TO REFORM THE CONCUSSION CARE MODEL.
Slide 12: End-to-end data strategy underpinning our competitive moat
Competitive Differentiator 12 End-to-end data strategy across care journey is underpinning our competitive moat. Our brain health platform aims to provide a holistic technology led ecosystem that supports the identification, monitoring and rehabilitation of sport- related brain injury (concussion &
Slide 13: World's first commercial end-to-end brain injury management platform
Strategy 13 World’s first commercial end-to-end brain injury management platform. Three pillar strategy driving our end-to-end vision three pillars 01 Surveillance & 02 Assessment, 03 Rehabilitation Detection Monitoring & Diagnosis Quantify Define Specific Re-training of Impact Loads Impairment impa
Slide 14: One technology platform targets all components of end-to-end journey
Solution 14 One technology platform provides opportunity to target all components of end-to-end journey. Surveillance Digital Virtual Reality Virtual Reality Brain System Assessment Tool Diagnostic Aid Injury Recovery Wearable sensor technology Leading concussion assessment Immersive, sensitive & Fu
Slide 15: Global leadership in impact sensor technology
Nexus Surveillance System 15 Global leadership in impact sensor technology. Purpose built wearable technology delivering validated brain impact data through sophisticated algorithms and machine learning methodologies. Only form factor able to validly collect head impact data due to positioning of se
Slide 16: Building a significant asset base of brain impact data
Nexus Surveillance System 16 Building a significant asset base of brain impact data across a well-developed data capture program. Data Capture Program 2 Data Capture Program 3 Scotland Rugby German Ice Hockey Data Capture Program 6 Data Capture Program 1 8 Tier 1 College football programs UFC across
Slide 17: Increasing data capability key area for future development
Nexus Surveillance System 17 Increasing Data capability key area for future development. Phase 1 Phase 2 Current Future Works Prototype Testing Data Data Data Predictive Collection Reporting analytics Analytics Descriptive Data Predictive Data HITIQ data shows: HITIQ databank is now Athletes playing
Slide 18: Strong Consumer Go-to-Market Strategic Partnerships for Nexus
Nexus Surveillance System 18 Strong Consumer Go-to-Market Strategic Partnerships for Nexus. Partnership to deliver technology into grass roots through the largest health insurer in Australasia. Providing subsidy to customers through existing health insurance policies. ► 257 dental clinics within Aus
Slide 19: Electronic record for standardized concussion assessment protocols
CSX Digital Assessment Tool 19 Electronic record for standardized CSX concussion assessment protocols. Vast databank of baseline and Head Impact Assessments (HIA) performed. Thousands of brains under managements through CSX platform. Critical compliance and digital record keeping tool for clinicians
Slide 20: Strong adoption from Elite Market to help launch CSX community platform
CSX Digital Assessment Tool 20 Strong adoption from Elite Market to help launch CSX community platform early 2023. CSX Current concussion management protocols in the community face the following challenges: ► The standard of care provided by general practitioners is extremely varied and mostly inept
Slide 21: Assessing the brain's cognitive performance with virtual reality
CoVR Virtual Reality Diagnostic Aid 21 Assessing the brain’s cognitive performance with virtual reality. Technology Background & Path to Market
Slide 22: Entry into an emerging technology sector
CoVR Technology Background 22 Entry into an emerging technology sector, opening access to a lucrative diagnostic market. The CoVR test protocol utilises an array of proprietary mini games designed to ensure a robust assessment of the various cognitive abilities that can be adversely affected by conc
Slide 23: New approach for cognitive assessment
CoVR Technology Background 23 New approach for cognitive assessment. Migrates traditional paper and subjective evaluations to a more sophisticated level and enhanced sensitivity. The system provides robust assessments that can assess cognitive skills in a more standardised, objective & reproducible
Slide 24: Designed to identify & define brain injury
CoVR Technology Background 24 Scientific Rational 01 Comprehensive Coverage Designed to identify & Concussions and longer-term impairment can define brain injury. present in a variety of ways across any domain, hence the importance for a comprehensive test suite. The CoVR test protocol utilises an a
Slide 25: Comprehensive Testing Across Multiple Domains
CoVR Technology Background 25 Comprehensive Testing Across Multiple Domains. Cognitive Domain Test 1 Verbal Learning & Immediate Recognition Memory Test 2 Processing Speed Test 3 Visual Motor Speed Test 4 Complex Processing Speed & Inhibitory Control Test 5 Complex Processing Speed, Inhibitory Contr
Slide 26: Regulatory Overview
CoVR Regulatory Pathway 26 Regulatory Overview. ► 510K required for Class II Medical Device classification as a Concussion Diagnostic Aid ► FDA Q-Sub has been submitted and a predicate device have been identified ► Ethics approved at each site for Studies 1, 2, 3 & 4 ► Commencing pre-clinical resear
Slide 27: Clinical Validation Pathway
CovR Regulatory Pathway 27 Clinical Validation Pathway. Complete Complete In Progress Prototype Review, Testing Regulatory System Validation Pre-Clinical Clinical Approval & Development Testing Trial Testing Trial Launch Study 1 - Normative Data Study 5 - Internal Validity v2 Study 2 - Construct Val
Slide 28: Results - Validation Testing
CoVR Current Standard of Care 28 Results - Validation Testing. A factor analysis compresses game outcomes into singular variables resulting in five factors. These factors represent specific cognitive domains - Inhibition, Reaction Speed, Perceptual Motor, Visual Working Memory and Memory. The blue b
Slide 29: Pre Clinical Testing Locations
CoVR Regulatory Pathway 29 Pre Clinical Testing Locations. Pre clinical testing is underway at a number of sites in Australia and North America following successful ethics applications. Upon completion of successful pre clinical testing, the Study 5 Clinical trial will commence. University of Califo
Slide 30: Pre-Clinical Trial Studies
CoVR Regulatory Pathway 30 Pre-Clinical Trial Studies. Study Study Study Study 01 Normative Data 02 Construct Validity 03 Reliability of Change 04 Internal Validity v1 Provides a database of age Demonstrate various subsets Evaluates the consistency of Evaluates the ability of the CoVR and gender str
Slide 31: Clinical Trial Study – Internal Validity v2
CoVR Regulatory Pathway 31 Clinical Trial Study 5 – Internal Validity v2. PARTICIPANTS LOCATION DURATION DESIGN Two cohorts will Multi-site Expected 6 Concussed athletes complete the CoVR enrolment months with will be assessed Protocol.; program. preliminary between 24 and 72 findings released hours
Slide 32: Market Opportunities
CoVR Path to Market 32 Market Opportunities Following Class II Medical Device Classification, a number of CPT codes would be available for use with CoVR. 96132 Neuropsychological testing evaluation. Includes integration of patient data, interpretation of results and clinical data, clinical decision
Slide 33: Trusted by the largest sporting codes & leagues
Market Traction 33 Trusted by the largest sporting codes & leagues across the globe to deliver highly "Football is an evolving sport, I am pleased that HITIQ's technology is improving our ability to quantify our valuable data. athletes head impacts“ BRETT MORTENSEN Brigham Young University Rehab Coo
Slide 34: Well positioned for growth across multiple sectors
Positioning 34 Well positioned for growth across multiple sectors. Technology Suite Consumer Growth Offering Pathways Established Robust R&D phase has delivered a Established partner portfolio to facilitate strong entry into scientifically validated technology consumer segment within local and inter
Slide 35: Strong building blocks of IP Portfolio
Positioning 35 Strong building blocks of IP Portfolio. Total Applications Provisional PCT National applications (15) (6) Fillings (32) Filed Current International Australia United States Europe NZ Canada Global (2) (19) (7) (5) (1) (1) Coverage Examination Patent Examination Awaiting Examination Und
Slide 36: Targeting a growing worldwide addressable market
Addressable Market 36 We're targeting a growing worldwide concussion-brain injury market including elite and community sport, & allied health segments. Accounts Athletes Nexus CSX CoVR HITIQ has established a ELITE SPORT 10k 500k $310m $28m $100m data subscription model Tier 1 for its integrated har
Slide 37: Future Value Inflection Points
Future Value Inflection Points 37 Near term news flow pipeline… ► NEXUS deal flow from various projects crystalising ► Expansion of consumer go-to-market distribution infrastructure ► Progress Shock Doctor relationship & entry into US consumer segment ► Extension of CSX technology into community ► P
Slide 38: Team
Team 38 BOARD OF DIRECTORS SCIENTIFIC & MEDICAL ADVISORY COUNCIL Honorary Associate Emeritus Professor Otto Buttula Aidan Clarke Glenn Smith Phil Carulli Professor Non-Executive Chairman Non-Executive Director Non-Executive Director Non-Executive Director Jeffrey V. Rosenfeld Andrew Gardner AC OBE E
Slide 39: End
End 39 empowering advanced concussion management - ENDS - Authorised for release by the Board of Directors. Mike Vegar Elvis Jurcevic CEO & MD Investor Relations HITIQ Limited +61 408 268 271 investors@hitiq.com ej@hitiq.com